For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Stelues Shipments to Get Back to Normal in September: Pfizer Japan
August 30, 2022
- Kymriah Now Approved for Follicular Lymphoma in Japan: Novartis
August 29, 2022
- Minomycin Supply Resumption to Be Delayed: Pfizer
August 26, 2022
- Pfizer Files Ritlecitinib for Alopecia Areata Treatment in Japan
August 26, 2022
- Meiji Pharma in Talks on Japan Rights to Arcturus’ COVID Jab Candidate
August 26, 2022
- Eisai, US Brain Health Diagnostics Provider Seal MOU to Boost Awareness, Development of Blood-Based Assays
August 25, 2022
- Sawai Breaks Ground on New Factory Building in Kyushu, Shipment Start Set for April 2024
August 24, 2022
- Sawai Chief Wants Expert Panel to Discuss Delisting of Generics Deemed No Longer Necessary
August 24, 2022
- Pfizer Continues to Halt Champix Shipments on Prolonged Fix of Manufacturing Process
August 24, 2022
- Takeda’s Dengue Vaccine Gets Its 1st Approval in Indonesia
August 24, 2022
- Daiichi Sankyo’s Quizartinib Accepted for European Review in 1st Line AML
August 24, 2022
- BMS Wants to Jolt Cancer Care Landscape with Broader I/O Combo Options, Pursuing LAG-3 Inhibitor in Japan Too
August 24, 2022
- All Companies Curbing Shipments of Meropenem, Top-Priority Drug Requiring Stable Supplies
August 23, 2022
- Chugai/Noile-Immune Ink Deal for PRIME CAR-T Technology to Create Solid Tumor Therapy
August 23, 2022
- Swiss Licensee ObsEva Withdraws NDA for Kissei’s Linzagolix in US
August 23, 2022
- Otsuka/Astex’s AML Medicine Accepted for Review in Europe
August 23, 2022
- Kyowa Kirin Bags European Approval for Crysvita in TIO
August 22, 2022
- Xofluza Approved in US for Children Aged 5 and Older
August 22, 2022
- Lagevrio Joins NHI Price List, Normal Distribution to Start Once Ready
August 19, 2022
- Astellas’ Hot Flash Med Accepted by FDA Review, Gets Short-Cut with Voucher Use
August 19, 2022
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…